| Web: | mayocliniclabs.com |
|---|---|
| Email: | mcl@mayo.edu |
| Telephone: | 800-533-1710 |
| International: | +1 855-379-3115 |
| Values are valid only on day of printing | |
| Web: | mayocliniclabs.com |
|---|---|
| Email: | mcl@mayo.edu |
| Telephone: | 800-533-1710 |
| International: | +1 855-379-3115 |
| Values are valid only on day of printing | |
Neurology testing overview
The rapid expansion of neurology testing has resulted in the discovery of increasing numbers of clinically relevant biomarkers. Mayo Clinic Laboratories collaborates closely with the clinical practice to develop and offer advanced testing — much of which is unavailable anywhere else — to address the most difficult questions.
Our laboratories are led by board-certified clinical neurologists and clinical chemists who have extensive experience using testing to guide patient care. These experts are available for consultations on test selection and results interpretation. Our physicians are committed to research and discovery to pave the way for the future of neurology testing.
Comprehensive disease testing
A collaboration with BioPharma Diagnostics includes access to the neurologic disease testing capabilities of Mayo Clinic Laboratories, including:
The latest
Mayo Clinic Laboratories has marked a significant advancement in the fight against Alzheimer's disease with the introduction of an innovative diagnostic test. This noninvasive blood test accurately detects the p-Tau217 biomarker, indicative of amyloid beta accumulation in the brain. This test is set to transform the approach to Alzheimer's disease management, offering a convenient and less invasive alternative to traditional diagnostic methods.
Andrew McKeon, M.B., B.Ch., M.D., explains how Mayo Clinic Laboratories' expanded movement disorders panel better identifies autoimmune conditions to guide appropriate treatment.
PACEIn this month’s “Virtual Lecture” Eoin Flanagan, M.D., B.Ch., reviews how to diagnose autoimmune encephalitis, what to watch that may suggest a different diagnosis, discuss neural autoantibodies interpretation and putting test results into clinical context.
Education on this topic decreases misdiagnosis and the possibility of misinterpreting the comments provided by the reporting laboratories.
As part of Mayo Clinic’s Neuro-Oncology practice, the Division of Laboratory Genetics and Genomics tests about 50 brain tumors a week, and upwards of 1,500 brain tumors a year from all over the world.
Ed Garber spent months in physical and neurological decline while a cohort of care providers and specialists searched for the root cause of his symptoms. That search for answers ended after testing by Mayo Clinic Laboratories gave them the confirmatory diagnosis they needed.
Linda Hasadsri, M.D., Ph.D., explains carrier screening at Mayo Clinic Laboratories. Using targeted genotyping, our three focused panels evaluate genes associated with cystic fibrosis, spinal muscular atrophy, and hemoglobinopathies, to provide clear answers on reproductive risks and to guide decision-making.
Andrew McKeon, M.B., B.Ch., M.D., explains how Mayo Clinic Laboratories' pediatric autoimmune/CNS testing can better guide the treatment of autoimmune neurological diseases in children. The tailored evaluation covers only biomarkers relevant to pediatric presentations of the diseases.
Divyanshu (Div) Dubey, M.B.B.S., describes Mayo Clinic Laboratories' new diagnostic test for CIDP, or chronic inflammatory demyelinating polyneuropathy. The new test detects two antibodies — NF155 and CNTN1 — to enhance diagnosis and guide treatment decisions. Often misdiagnosed, CIDP is treatable if detected early.
Mayo Clinic Laboratories offers an innovative testing solution for the early detection of Alzheimer's disease. Learn more at the AAIC 2022 tradeshow.
Joshua Bornhorst, Ph.D., describes the new, FDA-approved Alzheimer's disease (AD) test and how it differs from Mayo Clinic Laboratories' existing AD evaluation. The laboratory will offer both tests, to ensure flexibility and options for managing clinical care.
Mayo Clinic neuropathologist Caterina Giannini, M.D., Ph.D., received the American Association of Neuropathologists’ (AANP) award for Meritorious Contributions to Neuropathology during the AANP’s 98th annual meeting in June.
As a two-time brain tumor survivor, Alex Kraatz has been through more harrowing medical experiences in his 34 years than most people face in a lifetime. But Alex’s fighting spirit, coupled with precision laboratory testing and cutting-edge treatments, have propelled him forward, keeping him hopeful despite the odds.